Breast Biopsy Devices Market Size, Share | Industry Trend & Forecast 2024-2030

Breast Biopsy Devices Market Overview

Breast Biopsy Devices Market Size is valued at $3.4 Billion by 2030, and is anticipated to grow at a CAGR of 5.1% during the forecast period 2024 -2030. The breast biopsy device market is experiencing significant growth, driven by advancements in medical technology, rising incidence of breast cancer, and increasing awareness about early detection. Breast biopsy is a critical procedure for diagnosing breast cancer, involving the removal of tissue or fluid samples from a suspicious area in the breast for pathological examination. The market encompasses a variety of devices, including core needle biopsy (CNB), fine needle aspiration biopsy (FNAB), vacuum-assisted biopsy (VAB), and liquid biopsy systems.

One of the major trends in the breast biopsy device market is the increasing adoption of minimally invasive techniques. Procedures like VAB and CNB are preferred over traditional surgical biopsies due to their advantages, such as reduced patient discomfort, shorter recovery times, and lower risk of complications. These techniques involve the use of imaging guidance to accurately locate and target suspicious lesions, allowing for precise tissue sampling with minimal trauma to the surrounding tissue.

Market Snapshot:

COVID-19/Russia-Ukraine War Impact

The COVID-19 pandemic significantly impacted the Breast Biopsy Devices Market, initially disrupting supply chains and delaying elective medical procedures, including biopsies. Hospitals prioritized COVID-19 treatments, resulting in reduced demand for biopsy devices as non-urgent diagnostics were postponed. However, the pandemic also underscored the importance of robust healthcare infrastructure and advanced diagnostic capabilities. As healthcare systems adapted, there was a renewed focus on early disease detection and management, driving the need for reliable biopsy devices. Manufacturers responded by innovating and ensuring supply chain resilience. Telehealth advancements and remote diagnostics further influenced market dynamics, emphasizing the need for precision and efficiency in biopsy procedures. Consequently, while the market faced short-term setbacks, the long-term outlook remains positive, driven by the pandemic-induced acceleration in healthcare modernization and the heightened awareness of early diagnostic tools' critical role in patient outcomes.

The Russo-Ukraine War has disrupted the Breast Biopsy Devices Market, primarily through supply chain interruptions and geopolitical instability. The conflict has led to significant disruptions in the production and distribution of medical devices, with key manufacturing hubs and logistics routes impacted. Additionally, the economic sanctions and trade restrictions imposed on Russia have further complicated market dynamics, limiting access to essential components and raw materials. Healthcare systems in the affected regions are strained, diverting resources away from elective and non-urgent procedures, including biopsies. This has resulted in a decreased demand for biopsy devices in the short term. However, the heightened awareness of healthcare infrastructure resilience and the need for continuous medical advancements are prompting global stakeholders to invest in more stable and diversified supply chains. Consequently, while the immediate effects are negative, the long-term outlook includes a potential restructuring of the market towards greater robustness and adaptability.

Breast Biopsy Devices Market Report Coverage

The report “Breast Biopsy Devices Market Forecast (2024 – 2030)”, by Industry ARC, covers an in-depth analysis of the following segments of the Breast Biopsy Devices Market:

By Product: Needle-Based Biopsy Instruments (Core Biopsy Devices, Aspiration Biopsy Devices, Vacuum-Assisted Biopsy Devices), Procedure Trays, Localization Wires, Others

By Guidance Technique: Ultrasound-Guided, Stereotactic-Guided, MRI-Guided, CT-Guided, Others

By End-User: Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centers

By Type: Open Surgical Breast Biopsy Devices, Needle Breast Biopsy Devices

By Geography: North America (USA, Canada, and Mexico), South America (Brazil, Argentina, Colombia, Chile, and Rest of South America), Europe (UK, Germany, France, Italy, Netherlands, Spain, Russia, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Malaysia, and Rest of APAC), and Rest of the World (Middle East, and Africa)

Key Takeaways

• By guided technology, the Ultrasound guided biopsy is poised to be the fastest growing with a CAGR of 5.6% during the forecast period 2024-2030. This is owing to the demand for minimally invasive surgical procedures.
• Biopsy devices are used in different market verticals of the medical sector. Due to the widened applications, new openings for the subject market can be exploited, benefitting its growth throughout the forecast period.
• Modernization of traditional biopsy techniques is another key trend. New techniques like liquid biopsy are emerging, replacing the conventional methods, which is driving the growth of Breast Biopsy Devices Market during the forecast period 2024 – 2030.

For more details on this report - Request for Sample

Breast Biopsy Devices Market Segment Analysis – By Product

By Type the Needle Breast Biopsy held the largest market share in 2023 owing to the more accurate assessment of breast mass than fine needle aspiration since the larger core needle usually removes enough tissue for the pathologist to evaluate abnormal cells in relation to the surrounding small sample of breast tissue taken in the specimen. Ongoing research and development efforts are leading to technological innovations in the breast biopsy device market. Manufacturers are investing in the development of advanced biopsy devices that offer improved accuracy, safety, and ease of use. Innovations such as high-definition imaging systems, robotic-assisted biopsy devices, and the integration of artificial intelligence (AI) for image analysis are enhancing the capabilities of breast biopsy procedures. These technological advancements are expected to drive market growth by providing clinicians with more effective tools for the early detection and diagnosis of breast cancer.

Breast Biopsy Devices Market Segment Analysis – By Guidance Technique

Advancements in imaging technologies are significantly impacting the breast biopsy device market. The integration of ultrasound, magnetic resonance imaging (MRI), and mammography with biopsy procedures enhances the accuracy and efficiency of tissue sampling. These imaging modalities enable real-time visualization of the biopsy site, improving the precision of needle placement and ensuring the collection of representative tissue samples. The use of advanced imaging techniques also facilitates the detection of smaller lesions, contributing to earlier diagnosis and treatment of breast cancer. The development of automated and semi-automated biopsy systems is another key trend driving the market. These systems improve the efficiency and accuracy of biopsy procedures by automating certain steps, reducing the likelihood of human error, and enhancing procedural consistency. Automated systems also shorten the duration of the procedure, minimizing patient discomfort and anxiety. The continuous innovation in biopsy devices is leading to the introduction of user-friendly systems that provide better control, precision, and safety during the biopsy process.

Breast Biopsy Devices Market Segment Analysis – By End User

Hospitals accounted for the largest market share in 2023 owing to the increasing number of breast cancer patients around the world. Furthermore, trained doctors in the hospitals usually perform biopsy thereby hospital are a major place for biopsy. Moreover, in breast biopsy the doctor remove a small amount of tissue usually by a needle or surgery. In addition most of the surgical biopsies are done in hospital or surgical centers thereby driving the demand of breast biopsy during the forecast period 2024-2030. Liquid biopsy is an emerging trend in the breast biopsy device market, offering a less invasive alternative to traditional tissue biopsies. This technique involves the analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a blood sample. Liquid biopsy enables the detection of genetic mutations and biomarkers associated with breast cancer, providing valuable information for diagnosis, monitoring, and treatment planning. The growing interest in personalized medicine and the need for non-invasive diagnostic methods are driving the adoption of liquid biopsy techniques in clinical practice.

Breast Biopsy Devices Market Segment Analysis – By Geography

North America dominated the Breast Biopsy Devices Market with a region share 40% in 2023 followed by Europe and APAC. Increasing adoption of advanced medical technology and rising development by companies operating on cancer diagnostics is a major factor driving the Breast Biopsy Devices Market during the forecast period 2024-2030.Futhermore, growing awareness among people regarding early diagnosis and government initiatives are further contributing to its market growth. Moreover, according to U.S. Department of Health and Human Services more than 1 million people have breast biopsies each year in the U.S. About 20% of these biopsies yield a diagnosis of breast cancer which is driving the overall demand for the market.

Breast Biopsy Devices Market Drivers

Rising Prevalence of Breast Cancer

The rising prevalence of breast cancer globally is a significant driver of the breast biopsy device market. Breast cancer is one of the most common cancers among women, and early detection is crucial for effective treatment and improved survival rates. Increased awareness of breast cancer and the importance of regular screening have led to higher participation in screening programs, resulting in a greater number of biopsy procedures. Governments, healthcare organizations, and advocacy groups are actively promoting breast cancer awareness and screening, further boosting the demand for breast biopsy devices.

Technological Advancements in Breast Biopsy

Advancements in biopsy device technology are significantly driving the breast biopsy market. Innovations such as vacuum-assisted biopsy (VAB) systems, automated core needle biopsy devices, and advanced imaging-guided biopsy techniques have improved the accuracy, efficiency, and safety of breast biopsy procedures. These technological advancements reduce patient discomfort, shorten procedure times, and enhance diagnostic accuracy. Additionally, the development of minimally invasive biopsy methods and the integration of imaging technologies have expanded the range of biopsy options available to clinicians. The continuous evolution of biopsy devices and technologies is expected to drive market growth by providing improved diagnostic tools and enhancing patient outcomes.

Breast Biopsy Devices Market Challenges

Risk of Complications and Patient Anxiety

Breast biopsy procedures, although generally safe, can carry a risk of complications such as bleeding, infection, and pain. The fear of these potential complications can contribute to patient anxiety and reluctance to undergo biopsy procedures. Additionally, the psychological impact of a breast biopsy, including the stress of awaiting results and the possibility of a cancer diagnosis, can be significant for patients. Healthcare providers must prioritize patient education, provide clear communication, and implement strategies to minimize procedural risks and manage patient anxiety. Enhancing patient experience and addressing concerns related to biopsy procedures are essential to overcoming this challenge and ensuring the continued growth of the breast biopsy market.

Biopsy Devices Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Breast Biopsy Devices Market. The key companies in the Breast Biopsy Devices Market are:

1. Argon Medical Devices, Inc.
2. Becton, Dickinson and Company
3. GE Healthcare
4. B. Braun
5. Boston Scientific Corporation
6. Hologic, Inc.
7. Cardinal Health, Inc.
8. Cook Group Incorporated
9. Danaher Corporation (Mammotome)
10. Fujifilm Holdings Corporation

Recent Developments

• In May 2023, Argon Medical Devices launched the SuperCore Advantage, a new semi-automatic biopsy instrument for the U.S. market.
• In May 2022, Terumo India joined forces with Argon Medical to bring a wider range of medical solutions to the Indian market. By combining their strengths, they addressed the increasing need for advanced tools in biopsies, deep vein thrombosis treatments, and other procedures.
• In April 2023, GE Healthcare unveiled the bkActiv system, an advanced ultrasound imaging solution designed for surgical applications. This system empowers surgeons by providing real-time imaging and enhancing their decision-making during surgical procedures. 

For more Life science and Healthcare related reports, please click here